Aclaris Therapeutics, Inc. 10-Q

Item 5. Other Information ​ Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements. ​ During the quarter ended June 30, 2024, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K). ​ Item 6. Exhibits ​ ​ Exhibit No. Document ​ ​ ​ 3.1 ​ Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on October 13, 2015). ​ ​ ​ 3.2 ​ Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on August 7, 2023). ​ ​ ​ 3.3 ​ Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 24, 2020). ​ ​ ​ 10.1*˄ ​ Royalty Purchase Agreement, effective as of July 16, 2024, by and between the Registrant and OCM IP Healthcare Portfolio LP. ​ ​ ​ 31.1* ​ Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act. ​ ​ ​ 31.2* ​ Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act. ​ ​ ​ 32.1** ​ Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act. ​ ​ ​ 36 Table of Contents 101.INS ​ XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) ​ ​ ​ 101.SCH ​ Inline XBRL Taxonomy Extension Schema Document ​ ​ ​ 101.CAL ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ ​ 101.DEF ​ Inline XBRL Taxonomy Extension Definition Linkbase Document ​ ​ ​ 101.LAB ​ Inline XBRL Taxonomy Extension Label Linkbase Document ​ ​ ​ 101.PRE ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ ​ 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ​ * Filed herewith. ** These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. ˄ Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company has determined that the information is both not material and is the type that the Company treats as private or confidential. The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of the exhibit. Pursuant to Item 601(a)(5) of Regulation S-K promulgated by the SEC, certain exhibits and schedules to this agreement have been omitted. The Company hereby agrees to furnish supplementally to the SEC, upon its request, any or all of such omitted exhibits or schedules. ​ ​ ​ 37 Table of Contents SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ ​ ​ ​ ​ ACLARIS THERAPEUTICS, INC. ​ ​ ​ Date: August 7, 2024 By: /s/ Neal Walker ​ ​ Neal Walker ​ ​ Interim President and Chief Executive Officer ​ ​ (On behalf of the Registrant) ​ ​ ​ ​ ​ ​ Date: August 7, 2024 By: /s/ Kevin Balthaser ​ ​ Kevin Balthaser ​ ​ Chief Financial Officer ​ ​ (Principal Financial Officer) ​ ​ ​ 38